Mercury Labs board to meet on May 29 for FY26 results

1 min read Updated on 23 May 2026, 06:47 PM

Reviewed by

Suketu GScanX News Team

AI Summary

Mercury Laboratories Limited will hold a board meeting on May 29, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend for FY26, subject to shareholder approval. The trading window is currently closed and will reopen 48 hours post-results declaration.

*this image is generated using AI for illustrative purposes only.

Mercury Laboratories Limited has announced that its board of directors will meet on Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026, along with the draft Directors’ Report.

In addition to the financial results, the board will deliberate on recommending a dividend for the fiscal year ended March 31, 2026. Any dividend declared will be subject to the approval of shareholders at the ensuing Annual General Meeting.

The company has also informed the exchanges about the status of its trading window. Pursuant to the Company’s Code of Conduct for Prevention of Insider Trading, the window has been closed since April 01, 2026. It will remain closed until 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026.

Key Meeting Details

Agenda Item	Description
Financial Results	Audited results for Q4 and FY26
Dividend	Recommendation for FY26, if any
Meeting Date	May 29, 2026
Trading Window	Closed from April 01, 2026

Historical Stock Returns for Mercury Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-7.91%	+7.60%	+14.69%	-2.05%	-1.54%	+4.61%

How does Mercury Laboratories Limited's expected FY26 revenue and profit growth compare to its pharmaceutical sector peers, and what key business segments drove performance?

What dividend payout ratio is Mercury Laboratories likely to maintain given its historical dividend policy, and how might this signal management's confidence in future cash flows?

Following the board meeting on May 29, 2026, what strategic initiatives or capital allocation plans might the Directors' Report reveal for FY27?

Resignation Details

The company has provided comprehensive details about the senior management change in compliance with regulatory requirements:

Parameter:	Details
Name and Designation:	Mr. Sandip Patel, Plant Head-Jarod
Effective Date:	April 28, 2026 (Closure of business hours)
Reason:	Better opportunities and career advancement
Status:	Senior Management Personnel (SMP)

Regulatory Compliance

Mercury Laboratories has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was submitted to the Corporate Relations Department of BSE Limited, providing all necessary documentation including the resignation letter and detailed annexures.

The company confirmed that there are no other material reasons for the resignation beyond those stated in the formal resignation letter. Mr. Patel expressed gratitude for the opportunities, guidance, and support received during his tenure with the organization.

Management Transition

In his resignation letter dated April 28, 2026, Mr. Patel acknowledged the privilege of being part of Mercury Laboratories Limited and thanked the board members and colleagues for their guidance, support, and cooperation throughout his tenure. The resignation was formally accepted by the management on the same date.

The company has ensured proper documentation and regulatory compliance for this senior management transition, maintaining transparency with stakeholders and regulatory authorities.

Historical Stock Returns for Mercury Laboratories